Gossamer Bio (GOSS) Enterprise Value (2018 - 2026)
Gossamer Bio (GOSS) posted quarterly Enterprise Value of -$99.2 million for Q1 2026, up 61.53% year-over-year from -$61.4 million in Q1 2025, and up 27.54% quarter-over-quarter from -$136.9 million in Q4 2025.
Gossamer Bio (GOSS) Enterprise Value (2018 - 2026) Analysis & Trends
Gossamer Bio's Enterprise Value history runs 9 years deep, the most recent figure standing at -$99.2 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 61.53% year-over-year to -$99.2 million; the TTM figure through Mar 2026 stood at -$99.2 million (up 61.53% YoY), while the FY2025 annual figure was -$136.9 million, up 49.98% from the prior year.
- Enterprise Value for Q1 2026 stood at -$99.2 million, up from -$136.9 million in the prior quarter.
- The five-year high for Enterprise Value was -$39.9 million in Q3 2022, with the low at -$354.5 million in Q2 2024.
- The 5-year median for Enterprise Value is -$222.2 million (2022), against an average of -$213.9 million.
- Peak annual rise in Enterprise Value reached 81.31% in 2022, while the deepest fall reached 2440.52% in 2022.
- Gossamer Bio's Enterprise Value stood at -$255.7 million in 2022, then dropped by 15.94% to -$296.4 million in 2023, then increased by 7.65% to -$273.7 million in 2024, then soared by 49.98% to -$136.9 million in 2025, then rose by 27.54% to -$99.2 million in 2026.
- Business Quant data shows GOSS's Enterprise Value at -$99.2 million in Q1 2026, -$136.9 million in Q4 2025, and -$180.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.05 Bn | 131.20 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.49 Bn | 60.31 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 56.79 Bn | 51.65 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.05 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.71 Bn | 9.32 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 2.12 Bn |
| 10 | Gossamer Bio | 50.82 Mn | -6.21 Mn | - | -57.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -57.03 Mn |
| Mar 31, 2026 | -99.22 Mn |
| Dec 31, 2025 | -136.93 Mn |
| Sep 30, 2025 | -180.22 Mn |
| Jun 30, 2025 | -212.92 Mn |
| Mar 31, 2025 | -257.93 Mn |
| Dec 31, 2024 | -273.74 Mn |
| Sep 30, 2024 | -327.03 Mn |
| Jun 30, 2024 | -354.49 Mn |
| Mar 31, 2024 | -238.33 Mn |
| Dec 31, 2023 | -296.43 Mn |
| Sep 30, 2023 | -299.88 Mn |
| Jun 30, 2023 | -162.13 Mn |
| Mar 31, 2023 | -140.81 Mn |
| Dec 31, 2022 | -255.68 Mn |
| Sep 30, 2022 | -39.90 Mn |
| Jun 30, 2022 | -222.16 Mn |
| Mar 31, 2022 | -138.97 Mn |
| Dec 31, 2021 | -10.06 Mn |
| Sep 30, 2021 | -213.54 Mn |